## MOH: Molina Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.2% below STRENGTH zone (4.0-10.0%); PEG 2.54 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (55% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($140.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 2, Bearish: 4)

**1. Molina Has Dug A Narrow Moat in Its Government-Sponsored Plans**
- Source: Morningstar | 20251205T170837 | Bullish | Relevance: 100%
- Morningstar has initiated coverage of Molina Healthcare Inc. with a "Narrow Moat" rating and a fair value estimate of $311. Molina specializes in government-sponsored medical insurance plans (Medicaid, Medicare, and individual exchanges), focusing on cost management to generate economic profits. This strategy appears to successfully secure business in its key markets.

**2. MOH Deadline Today: MOH Investors Have Opportunity to Lead Molina Healthcare, Inc. Securities Fraud Lawsuit**
- Source: Morningstar | 20251203T150925 | Bearish | Relevance: 100%
- The Rosen Law Firm reminds investors who purchased Molina Healthcare, Inc. (NYSE: MOH) securities between February 5, 2025, and July 23, 2025, of the December 2, 2025, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Molina failed to disclose material adverse facts regarding its medical cost trend assumptions and financial guidance, leading to investors suffering damages. Investors can join the class action to potentially recover compensation without upfront fees.

**3. Invesco Ltd. Purchases 329,759 Shares of Molina Healthcare, Inc $MOH**
- Source: MarketBeat | 20251205T121118 | Somewhat-Bearish | Relevance: 100%
- Invesco Ltd. increased its stake in Molina Healthcare, Inc (NYSE:MOH) by 25.9% in the second quarter, acquiring an additional 329,759 shares to hold a total of 1,601,574 shares valued at approximately $477.1 million. Institutional investors now own about 98.5% of Molina Healthcare's stock. Despite an EPS miss, Molina Healthcare reported a revenue beat, and analysts currently maintain a consensus "Hold" rating with an average target price of $198.93.

**4. Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Molina Healthcare, Inc. (MOH) And Encourages Investors to Reach Out**
- Source: www.yourerie.com | 20251204T160910 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Molina Healthcare, Inc. (MOH). The firm encourages investors who purchased Molina securities before February 5, 2025, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis for class actions and shareholder derivative suits.

**5. Edgestream Partners L.P. Invests $3.97 Million in Molina Healthcare, Inc $MOH**
- Source: MarketBeat | 20251204T140841 | Somewhat-Bearish | Relevance: 100%
- Edgestream Partners L.P. has acquired a new position of 13,318 shares in Molina Healthcare, Inc (MOH) during the second quarter, valued at approximately $3.97 million. This comes as institutional ownership in Molina Healthcare is high, with several firms increasing their stakes, despite the company missing quarterly EPS expectations and analysts trimming their ratings to an average "Hold." Molina Healthcare's stock currently trades near $149, with a significant year-long range of $133 to $360.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-12 | Wells Fargo | $165 | $231 | -29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-12 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.44M) |
| Sells | 1 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.1%)
- Capital World Invest: 9.5% (-2.0%)
- Blackrock Inc.: 8.4% (-3.9%)
- Price (T.Rowe) Assoc: 6.5% (+58.8%)
- AQR Capital Manageme: 5.4% (+217.0%)

### Key Risks

1. Elevated short interest (9.4%): bears positioning against stock.
2. Long-term trend broken: trading 35.9% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.54 signals overvaluation risk, limited margin of safety. Forward P/E 9.2x attractive for 18% earnings growth. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.9B |
| Beta | 0.52 |
| 52W Range | $133.40 - $359.97 |
| Short Interest | 9.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.54 |
| Forward P/E | 9.2 |
| Current P/E | 10.9 |
| YoY Growth | 18.1% |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -0.2% to 3.2% (+3.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >4.0% for momentum thesis). MRS_5 at 1.7% confirms short-term momentum alignment. AM_20 at 5.6% shows strong absolute momentum above own 20MA. Outperforming sector by 5.5pp, stock-specific strength. Below SMA200 (0.64x), long-term trend not supportive. MACD histogram positive (2.62), confirming momentum. RSI neutral at 51. Volume at 55% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.20% (CS: 76) | Neutral |
| RSI_14 | 51.1 | Neutral |
| MACD Histogram | 2.62 | Bullish |
| vs SMA20 | 1.056x | Above |
| vs SMA50 | 0.914x | Below |
| vs SMA200 | 0.641x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $151.86
- **Stop Loss:** $140.90 (7.2% risk)
- **Target:** $162.82 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 45
- **Position Value:** $6,833.70
- **Portfolio %:** 6.83%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-04 (Est: $0.64)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.89 | $1.84 | -52.7% |
| 2025Q2 | $5.53 | $5.48 | -0.9% |
| 2025Q1 | $5.96 | $6.08 | +2.0% |
| 2024Q4 | $5.88 | $5.05 | -14.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*